{"id":"acthar-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Mood changes / psychiatric effects"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Fluid retention / edema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acthar binds to melanocortin-2 receptors on adrenocortical cells, triggering the release of endogenous glucocorticoids and mineralocorticoids. This endogenous steroid production provides anti-inflammatory and immunosuppressive effects. Unlike exogenous corticosteroids, Acthar stimulates the body's own steroid synthesis, which may offer different pharmacodynamic properties and potentially preserve some aspects of adrenal function.","oneSentence":"Acthar is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:08.350Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infantile spasms (West syndrome)"},{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Polymyositis and dermatomyositis"},{"name":"Acute exacerbations of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":"Sleep Restriction","enrollment":5},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":"Sleep Restriction","enrollment":80},{"nctId":"NCT02813655","phase":"PHASE2","title":"Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Post-dural Puncture Headache","enrollment":46},{"nctId":"NCT06964269","phase":"PHASE4","title":"Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease","status":"RECRUITING","sponsor":"Toyos Clinic","startDate":"2025-02-11","conditions":"Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis","enrollment":20},{"nctId":"NCT05696613","phase":"PHASE3","title":"A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"Cerium Pharmaceuticals, Inc.","startDate":"2023-03-13","conditions":"Primary Membranous Nephropathy","enrollment":148},{"nctId":"NCT03511625","phase":"PHASE3","title":"The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Attune Health Research, Inc.","startDate":"2018-10-02","conditions":"Rheumatoid Arthritis","enrollment":6},{"nctId":"NCT03727776","phase":"EARLY_PHASE1","title":"Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-08-19","conditions":"Proliferative Vitreoretinopathy","enrollment":11},{"nctId":"NCT05546047","phase":"PHASE4","title":"A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients","status":"UNKNOWN","sponsor":"NephroNet, Inc.","startDate":"2019-03-14","conditions":"Fibrillary Glomerulonephritis","enrollment":34},{"nctId":"NCT04080076","phase":"PHASE4","title":"Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy","status":"WITHDRAWN","sponsor":"NephroNet, Inc.","startDate":"2019-01-12","conditions":"Renal Disease","enrollment":""},{"nctId":"NCT03025828","phase":"PHASE4","title":"Adrenocorticotropic Hormone in Membranous Nephropathy","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-03-19","conditions":"Membranous Nephropathy","enrollment":5},{"nctId":"NCT01960530","phase":"PHASE1","title":"An Investigational Study of Hydrocortisone","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2013-10","conditions":"Adrenal Insufficiency","enrollment":14},{"nctId":"NCT02399462","phase":"PHASE4","title":"Acthar for Treatment of Post-transplant FSGS","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-03","conditions":"FSGS, Renal Transplantation, Kidney Transplantation","enrollment":""},{"nctId":"NCT02633046","phase":"PHASE4","title":"Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria","status":"COMPLETED","sponsor":"Mallinckrodt ARD LLC","startDate":"2016-10-10","conditions":"Idiopathic Focal Segmental Glomerulosclerosis","enrollment":63},{"nctId":"NCT02749227","phase":"PHASE2","title":"Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors","status":"TERMINATED","sponsor":"Columbia University","startDate":"2017-07-10","conditions":"Pituitary Tumor, ACTH-producing Pituitary Tumour","enrollment":4},{"nctId":"NCT03068754","phase":"PHASE2, PHASE3","title":"Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2017-06-22","conditions":"Amyotrophic Lateral Sclerosis","enrollment":143},{"nctId":"NCT02290444","phase":"PHASE3","title":"Effects of Acthar on Recovery From Cognitive Relapses in MS","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2013-08","conditions":"Multiple Sclerosis","enrollment":64},{"nctId":"NCT01753401","phase":"PHASE4","title":"Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2013-01","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":38},{"nctId":"NCT02315872","phase":"PHASE3","title":"ACTH for Fatigue in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2015-05-22","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":8},{"nctId":"NCT03408405","phase":"PHASE4","title":"ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2018-06","conditions":"Steroid-Resistant Nephrotic Syndrome","enrollment":""},{"nctId":"NCT01987167","phase":"EARLY_PHASE1","title":"Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis","status":"COMPLETED","sponsor":"Neuro-Ophthalmologic Associates, PC","startDate":"2013-11","conditions":"Optic Neuritis","enrollment":25},{"nctId":"NCT02394457","phase":"PHASE4","title":"Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache","status":"COMPLETED","sponsor":"United States Naval Medical Center, San Diego","startDate":"2010-08","conditions":"Postdural Puncture Headache","enrollment":29},{"nctId":"NCT01984177","phase":"","title":"Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2013-06","conditions":"Cocaine-Related Disorders, Cocaine Addiction, Substance-Related Disorders","enrollment":17},{"nctId":"NCT02574962","phase":"PHASE2","title":"Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy","status":"WITHDRAWN","sponsor":"Mamatha Pasnoor, MD","startDate":"2015-08","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["repository corticotropin injection","H.P. Acthar Gel"],"phase":"phase_3","status":"active","brandName":"Acthar Injectable Product","genericName":"Acthar Injectable Product","companyName":"Attune Health Research, Inc.","companyId":"attune-health-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acthar is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids. Used for Infantile spasms (West syndrome), Rheumatoid arthritis, Systemic lupus erythematosus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}